Difference between revisions of "Radium-223 (Xofigo)"
m |
m |
||
| Line 19: | Line 19: | ||
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
*2013-11-13: Initial marketing authorization as Xofigo. | *2013-11-13: Initial marketing authorization as Xofigo. | ||
| + | ==History of changes in Health Canada indication== | ||
| + | *2013-12-12: Initial notice of compliance (details unavailable) | ||
==Also known as== | ==Also known as== | ||
| Line 35: | Line 37: | ||
[[Category:EMA approved in 2013]] | [[Category:EMA approved in 2013]] | ||
[[Category:FDA approved in 2013]] | [[Category:FDA approved in 2013]] | ||
| + | [[Category:Health Canada approved in 2013]] | ||
Revision as of 00:37, 12 May 2023
General information
Class/mechanism: Radioactive pharmaceutical agent (radium-223) that mimics some biologic behaviors of calcium and is incorporated into areas with increased bone turnover, such as bone metastases, by forming complexes with hydroxyapatite. Radium-223 emits alpha radiation at the site of bone metastases, which causes double-strand DNA breaks in nearby cells. The limited penetration of alpha radiation (less than 100 micrometers/uM, less than 10 cell diameters) is believed to limit the risk of adverse side effects. Radium-223's half-life is 11.4 days. Its specific activity is 1.9 MBq (51.4 microcurie)/ng; molecular weight of 223RaCl2: 293.9 g/mol.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Radium-223 (Xofigo) patient drug information (Chemocare)[4]
- Brief patient counseling information can be found in the Radium-223 (Xofigo) package insert[1]
History of changes in FDA indication
- 2013-05-15: FDA approved for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease. (Based on ALSYMPCA)
History of changes in EMA indication
- 2013-11-13: Initial marketing authorization as Xofigo.
History of changes in Health Canada indication
- 2013-12-12: Initial notice of compliance (details unavailable)
Also known as
- Generic names: Ra-223, Radium Ra 223 dichloride, Radium-223 chloride
- Brand names: Alpharadin, Xofigo